

November 08, 2024

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Reg.: Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is in continuation to:

- our letter dated September 12, 2024 intimating that the U.S. Government's development finance institution, the U.S. International Development Finance Corporation (DFC) has committed a long-term loan of up to US\$20 million to Panacea Biotec; and
- our letter dated October 30, 2024, intimating the date of proposed Board Meeting scheduled to be held on Wednesday, November 13, 2024, for inter-alia considering and approving the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30, 2024.

Pursuant to Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable rules and regulations, we would like to inform that the Board of Directors in the said Board Meeting would also, inter-alia, consider and approve raising of funds through External Commercial Borrowings from DFC for an amount upto US\$ 20 million (equivalent to (~Rs.168.16 Crore), in one or more tranches, as may be permitted under applicable laws.

This is for your kind information and record please.

Thanking you,
Sincerely yours,
For **Panacea Biotec Limited**

Vinod Goel
Group CFO and Head Legal
& Company Secretary